Setting

Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity

Published: 28 Sep 2020 | Report Code: 10247703 | Pages: 125

Europe pharmacogenomics market accounted for $1,565.6 million in 2019 and will grow by 7.1% annually over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic. Highlighted with 38 tables and 50 figures, this 125-page report “Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country. Based on Service, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Genotyping • SNP Identification • Diagnostics • Other Services Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Polymerase Chain Reaction (PCR) • Microarray • Sequencing • Electrophoresis • Mass Spectrometry • Other Technologies Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oncology • Infectious Diseases • Neurology/Psychiatry • Cardiovascular • Pain Management • Other Applications Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals and Clinics • Pharmaceutical Companies • Research Institutes Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): 23andMe, Inc. Abbott Laboratories Admera Health, LLC Agena Biosciences, Inc. Astra Zeneca PLC Bayer AG Becton, Dickinson and Company Cancer Genetics, Inc. Dynamic DNA Laboratories Empire Genomics LLC F. Hoffmann-La Roche Ltd geneOmbio Technologies Pvt Ltd. Genomic Health, Inc. Illumina, Inc. Laboratory Corporation of America Holdings Myriad Genetics Inc. Oneome LLC Opko Health, Inc. Pathway Genomics Corporation QIAGEN N.V. Quest Diagnostics Incorporated Teva Pharmaceuticals Industries Ltd. Thermo Fisher Scientific Inc. Transgenomic, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	9
1.2 Research Methodology	12
1.2.1 Overview of Market Research Methodology	12
1.2.2 Market Assumption	13
1.2.3 Secondary Data	13
1.2.4 Primary Data	13
1.2.5 Data Filtration and Model Design	15
1.2.6 Market Size/Share Estimation	16
1.2.7 Research Limitations	17
1.3 Executive Summary	18
2 Market Overview and Dynamics	21
2.1 Market Size and Forecast	21
2.1.1 Impact of COVID-19 on the Market	25
2.2 Major Growth Drivers	27
2.3 Market Restraints and Challenges	31
2.4 Emerging Opportunities and Market Trends	34
2.5 Porter’s Fiver Forces Analysis	38
3 Segmentation of Europe Market by Service	42
3.1 Market Overview by Service	42
3.2 Genotyping	44
3.3 SNP Identification	45
3.4 Diagnostics	46
3.5 Other Services	48
4 Segmentation of Europe Market by Technology	49
4.1 Market Overview by Technology	49
4.2 Polymerase Chain Reaction (PCR)	51
4.3 Microarray	52
4.4 Sequencing	53
4.5 Electrophoresis	54
4.6 Mass Spectrometry	55
4.7 Other Technologies	56
5 Segmentation of Europe Market by Application	57
5.1 Market Overview by Application	57
5.2 Oncology	59
5.3 Infectious Diseases	60
5.4 Neurology/Psychiatry	61
5.5 Cardiovascular	63
5.6 Pain Management	64
5.7 Other Applications	65
6 Segmentation of Europe Market by End User	66
6.1 Market Overview by End User	66
6.2 Hospitals and Clinics	68
6.3 Pharmaceutical Companies	69
6.4 Research Institutes	70
7 European Market 2019-2030 by Country	71
7.1 Overview of European Market	71
7.2 Germany	74
7.3 UK	76
7.4 France	79
7.5 Spain	81
7.6 Italy	83
7.7 Russia	85
7.8 Rest of European Market	87
8 Competitive Landscape	89
8.1 Overview of Key Vendors	89
8.2 New Product Launch, Partnership, Investment, and M&A	93
8.3 Company Profiles	94
23andMe, Inc.	94
Abbott Laboratories	96
Admera Health, LLC	97
Agena Biosciences, Inc.	98
Astra Zeneca PLC	99
Bayer AG	100
Becton, Dickinson and Company	101
Cancer Genetics, Inc.	102
Dynamic DNA Laboratories	103
Empire Genomics LLC	104
F. Hoffmann-La Roche Ltd	105
geneOmbio Technologies Pvt Ltd.	106
Genomic Health, Inc.	107
Illumina, Inc.	108
Laboratory Corporation of America Holdings	109
Myriad Genetics Inc.	110
Oneome LLC	111
Opko Health, Inc.	112
Pathway Genomics Corporation	113
QIAGEN N.V.	114
Quest Diagnostics Incorporated	115
Teva Pharmaceuticals Industries Ltd.	116
Thermo Fisher Scientific Inc.	117
Transgenomic, Inc.	118
9 Investing in Europe Market: Risk Assessment and Management	119
9.1 Risk Evaluation of Europe Market	119
9.2 Critical Success Factors (CSFs)	122
Related Reports and Products	125
List Of Tables

Table 1.  Snapshot of Europe Pharmacogenomics Market, 2019-2030	19
Table 2. Web-based Resources of Pharmacogenomics	24
Table 3.  Main Product Trends and Market Opportunities in Europe Pharmacogenomics Market	34
Table 4. Europe Pharmacogenomics Market by Service, 2019-2030, $ mn	42
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing	47
Table 6. Europe Pharmacogenomics Market by Technology, 2019-2030, $ mn	49
Table 7. Europe Pharmacogenomics Market by Application, 2019-2030, $ mn	57
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry	62
Table 9. Europe Pharmacogenomics Market by End User, 2019-2030, $ mn	66
Table 10. Europe Pharmacogenomics Market by Country, 2019-2030, $ mn	73
Table 11. Germany Pharmacogenomics Market by Service, 2019-2030, $ mn	75
Table 12. Germany Pharmacogenomics Market by Technology, 2019-2030, $ mn	75
Table 13. Germany Pharmacogenomics Market by Application, 2019-2030, $ mn	75
Table 14. UK Pharmacogenomics Market by Service, 2019-2030, $ mn	78
Table 15. UK Pharmacogenomics Market by Technology, 2019-2030, $ mn	78
Table 16. UK Pharmacogenomics Market by Application, 2019-2030, $ mn	78
Table 17. France Pharmacogenomics Market by Service, 2019-2030, $ mn	80
Table 18. France Pharmacogenomics Market by Technology, 2019-2030, $ mn	80
Table 19. France Pharmacogenomics Market by Application, 2019-2030, $ mn	80
Table 20. Spain Pharmacogenomics Market by Service, 2019-2030, $ mn	82
Table 21. Spain Pharmacogenomics Market by Technology, 2019-2030, $ mn	82
Table 22. Spain Pharmacogenomics Market by Application, 2019-2030, $ mn	82
Table 23. Italy Pharmacogenomics Market by Service, 2019-2030, $ mn	84
Table 24. Italy Pharmacogenomics Market by Technology, 2019-2030, $ mn	84
Table 25. Italy Pharmacogenomics Market by Application, 2019-2030, $ mn	84
Table 26. Russia Pharmacogenomics Market by Service, 2019-2030, $ mn	86
Table 27. Russia Pharmacogenomics Market by Technology, 2019-2030, $ mn	86
Table 28. Russia Pharmacogenomics Market by Application, 2019-2030, $ mn	86
Table 29. Pharmacogenomics Market in Rest of Europe by Country, 2019-2030, $ mn	88
Table 30. Product Approvals by Company, January 2016 – April 2019	91
Table 31. Breakdown of Europe Market by Key Vendor, 2019, %	91
Table 32. 23andMe, Inc.: Company Snapshot	94
Table 33. 23andMe, Inc.: Business Segmentation	94
Table 34. 23andMe, Inc.: Product Portfolio	95
Table 35. 23andMe, Inc.: Revenue, 2016-2018, $ mn	95
Table 36. 23andMe, Inc.: Recent Developments	95
Table 37.  Risk Evaluation for Investing in Europe Market, 2019-2030	120
Table 38. Critical Success Factors and Key Takeaways	123
List Of Figures

Figure 1. Research Method Flow Chart	12
Figure 2. Breakdown of Primary Research	14
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	16
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	18
Figure 5. Europe Pharmacogenomics Market, 2019-2030, $ mn	21
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice	23
Figure 7. Impact of COVID-19 on Business	25
Figure 8. Primary Drivers and Impact Factors of Europe Pharmacogenomics Market	27
Figure 9. World Top 10 Causes of Deaths, 2016	30
Figure 10. Primary Restraints and Impact Factors of Europe Pharmacogenomics Market	31
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics	33
Figure 12. Investment Opportunity Analysis	35
Figure 13. Porter’s Fiver Forces Analysis of Europe Pharmacogenomics Market	38
Figure 14. Breakdown of Europe Pharmacogenomics Market by Service, 2019-2030, % of Revenue	42
Figure 15. Europe Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%)	43
Figure 16. Europe Pharmacogenomics Market: Genotyping, 2019-2030, $ mn	44
Figure 17. Europe Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn	45
Figure 18. Europe Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn	46
Figure 19. Europe Pharmacogenomics Market: Other Services, 2019-2030, $ mn	48
Figure 20. Breakdown of Europe Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue	49
Figure 21. Europe Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)	50
Figure 22. Europe Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn	51
Figure 23. Europe Pharmacogenomics Market: Microarray, 2019-2030, $ mn	52
Figure 24. Europe Pharmacogenomics Market: Sequencing, 2019-2030, $ mn	53
Figure 25. Europe Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn	54
Figure 26. Europe Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn	55
Figure 27. Europe Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn	56
Figure 28. Breakdown of Europe Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue	57
Figure 29. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)	58
Figure 30. Europe Pharmacogenomics Market: Oncology, 2019-2030, $ mn	59
Figure 31. Europe Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn	60
Figure 32. Europe Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn	61
Figure 33. Europe Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn	63
Figure 34. Europe Pharmacogenomics Market: Pain Management, 2019-2030, $ mn	64
Figure 35. Europe Pharmacogenomics Market: Other Applications, 2019-2030, $ mn	65
Figure 36. Breakdown of Europe Pharmacogenomics Market by End User, 2019-2030, % of Revenue	66
Figure 37. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)	67
Figure 38. Europe Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn	68
Figure 39. Europe Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn	69
Figure 40. Europe Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn	70
Figure 41. Breakdown of European Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue	72
Figure 42. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)	73
Figure 43.  Pharmacogenomics Market in Germany, 2019-2030, $ mn	74
Figure 44.  Pharmacogenomics Market in UK, 2019-2030, $ mn	76
Figure 45.  Pharmacogenomics Market in France, 2019-2030, $ mn	79
Figure 46.  Pharmacogenomics Market in Spain, 2019-2030, $ mn	81
Figure 47.  Pharmacogenomics Market in Italy, 2019-2030, $ mn	83
Figure 48.  Pharmacogenomics Market in Russia, 2019-2030, $ mn	85
Figure 49.  Pharmacogenomics Market in Rest of Europe, 2019-2030, $ mn	87
Figure 50. Growth Stage of Europe Pharmacogenomics Industry over the Forecast Period	89

Key Players (this may not be a complete list and extra companies can be added upon request): 
3M Health Care Limited 
Adherium Limited 
Amiko Digital Health Limited 
AsthmaMD 
AstraZeneca plc 
Boehringer Ingelheim International GmbH 
Capsule Technologies, Inc. 
Cohero Health 
GlaxoSmithKline plc 
Kaia Health Software GmbH 
Medical International Research (MIR) 
Novartis AG 
NuvoAir 
Reciprocal Labs (Propeller Health) 
Sensiron AG 
Tactio Health 
Teva Pharmaceuticals Industries Ltd.